sBLA Accepted for Xiaflex for Peyronie's Disease

Share this article:

Auxilium Pharmaceuticals announced that the FDA has accepted for review its supplemental Biologics License Application (sBLA) for Xiaflex (collagenase clostridium histolyticum or CCH) for the treatment of Peyronie's disease (PD). Under the Prescription Drug User Fee Act (PDUFA), an action date is anticipated on September 6, 2013.

Xiaflex consists of a highly purified combination of two subtypes of collagenase, derived from Clostridium histolyticum, in specific proportion.  Together, the collagenase sub-types work synergistically to break the bonds of the triple helix collagen structure more effectively than human collagenase.

Xiaflex is currently approved for the treatment of adult Dupuytren's contracture patients with a palpable cord.   

For more information call (877) 663-0412 or visit www.auxilium.com.

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs